Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a report released on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock.

Several other equities research analysts also recently issued reports on ONCY. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Leede Financial downgraded Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th.

Oncolytics Biotech Price Performance

Shares of NASDAQ:ONCY opened at $0.69 on Monday. The company’s 50-day moving average price is $0.86 and its two-hundred day moving average price is $0.98. The stock has a market capitalization of $55.21 million, a PE ratio of -2.56 and a beta of 1.29. Oncolytics Biotech has a one year low of $0.67 and a one year high of $1.53.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC bought a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 29,744 shares of the company’s stock, valued at approximately $27,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.